'Transfersome-embedded-gel' for dual-mechanistic delivery of anti-psoriatic drugs to dermal lymphocytes

• Published in: Journal of microencapsulation 2022-08, Vol.39 (6), p.495-511
• Main Authors: Todke, Pooja, Polaka, Suryanarayana, Raval, Nidhi, Gondaliya, Piyush, Tambe, Vishakha, Maheshwari, Rahul, Kalia, Kiran, Tekade, Rakesh Kumar
• Format: Article
• Language: English
• Subjects: Clobetasol; Cyclosporine - therapeutic use; dermal delivery; dual- anti-psoriatic action; Humans; lipid-based drug delivery system; Lymphocytes - pathology; Pharmaceutical Preparations; Psoriasis; Psoriasis - drug therapy; Psoriasis - pathology; transfersome-embedded-gel; Tumor Necrosis Factor-alpha
• ISSN: 0265-2048; 1464-5246
• DOI: 10.1080/02652048.2022.2116119

Develop a platform for co-delivering clobetasol propionate (CP) and cyclosporine (CyA) to the epidermis and dermis to treat psoriasis. The transfersomes were prepared by thin-film hydration method. Transfersomes were characterised by dynamic light scattering and transmission electron microscope (TEM). Then, the gel stability, viscosity, pH, and spreadability were measured. Cytotoxicity of the CyA-loaded transfersome embedded in CP-dispersed gel (TEG-CyA-CP) was assessed on both human keratinocyte cell line (HaCaT) and Jurkat cells. In vitro cellular uptake and ex vivo dermal distribution was measured. The expression of inflammatory markers was assessed by reverse-transcription PCR (RT-PCR). Nanoscale (86%) were made. TEG-CyA-CP demonstrated higher viscosity (4808.8 ± 12.01 mPas), which may help control dual drug release. Ex vivo results showed TEG-CyA-CP ability to deliver CyA in the dermis and CP in the epidermis. RT-PCR studies showed the optimised formulation helps reduce the tumour necrosis factor (TNF-α) and interleukin-1 (IL-1) levels to relieve psoriasis symptoms. The developed TEG-CyA-CP represents a promising fit-to-purpose delivery platform for the dual-site co-delivery of CyA and CP in treating psoriasis.